ADC Toxicity Summit
July 25 - 27, 2023 - MA USHanson Wade Group
info@hansonwade.com
Phone:(+1) 617 455 4188
There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. The first-of-its-kind ADC Toxicity Summit will allow companies developing ADCs to overcome toxicological related challenges, by hearing case-study-led presentations on approved ADCs, including ImmunoGen's Mirvetuximab Soravtansine, as well as important scientific and strategic discussions. Designed to provide you with the toolkit to design and deliver more tolerable ADCs to patients without lowering efficacy this is your exclusive opportunity to join peers with expertise in toxicology, safety, and pathology. The ADC Toxicity Summit is your perfect platform to overcome where others have failed and accelerate more ADCs through preclinical development into the clinic and to market.